BENEVOLENTAI BIO LIMITED – Trademark Portfolio

Entity Type: 24

BENEVOLENTAI BIO LIMITED holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BENEVOLENTAI. The owner is based in LONDON.

4-8 MAPLE STREET

LONDON W1T5HD , GB

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BENEVOLENTAI BIO LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does BENEVOLENTAI BIO LIMITED have?

BENEVOLENTAI BIO LIMITED has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does BENEVOLENTAI BIO LIMITED file in?

BENEVOLENTAI BIO LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.

What are BENEVOLENTAI BIO LIMITED's most well-known trademarks?

BENEVOLENTAI BIO LIMITED's registered trademark portfolio includes well-known marks such as BENEVOLENTAI. These are among 1 currently registered trademark in the portfolio.

What is BENEVOLENTAI BIO LIMITED's trademark registration success rate?

BENEVOLENTAI BIO LIMITED has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.